Sabra Health Care price target raised to $20 from $18 at Truist

Truist analyst Michael Lewis raised the firm’s price target on Sabra Health Care (SBRA) to $20 from $18 and keeps a Hold rating on the shares. The REIT has a strong balance sheet and the stock has performed well year-to-date, though the company is not as low levered as several peers and, despite trading near the high end of its 10-year stock valuation range, its current cost of equity leaves relatively little room for immediate earnings accretion, the analyst tells investors in a research note.